Emerging Antibody-based Products

  • Kevin J. WhaleyEmail author
  • Josh Morton
  • Steve Hume
  • Ernie Hiatt
  • Barry Bratcher
  • Victor Klimyuk
  • Andrew Hiatt
  • Michael Pauly
  • Larry Zeitlin
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 375)


Antibody-based products are not widely available to address many global health challenges due to high costs, limited manufacturing capacity, and long manufacturing lead times. There are now tremendous opportunities to address these industrialization challenges as a result of revolutionary advances in plant virus-based transient expression. This review focuses on some antibody-based products that are in preclinical and clinical development, and have scaled up manufacturing and purification (mg of purified mAb/kg of biomass). Plant virus-based antibody products provide lower upfront cost, shorter time to clinical and market supply, and lower cost of goods (COGs). Further, some plant virus-based mAbs may provide improvements in pharmacokinetics, safety and efficacy.


Antibody magnICON Industrialization Nicotiana Products Manufacturing Transient Expression Gemini Glycan Modification 

List of abbreviations and acronyms


monoclonal antibody


human immunodeficiency virus


herpes simplex virus


respiratory syncytial virus


xylose and fucose knockout


Chinese hamster ovary


glycoprotein D


Non-Hodgkin’s lymphoma


follicular B-cell lymphoma


human like biantennary N-glycans with terminal N-acetylglucosamine on each branch


ceramic hydroxyapatite



Some of the work described was supported by grant numbers U19AI096398, AI62150, AI061270, AI063681, from NIAID, DAMD 17-02-2-0015 from the department of defense, and partially supported by the defense threat reduction agency grant no. 4.10007-08-RD-B. The content is solely the responsibility of the authors and does not necessarily represent the official views of the national institutes of health, U.S. Army, or department of defense.


  1. BARDA Strategic plan 2011–2016Google Scholar
  2. Bendandi M (2006) Clinical benefit of idiotype vaccines: too many trials for a clever demonstration. Rev Recent Clin Trials 1:67–74PubMedCrossRefGoogle Scholar
  3. Bendandi M (2008) Aiming at a curative strategy for follicular lymphoma. CA Cancer J Clin 58:305–317PubMedCrossRefGoogle Scholar
  4. Bendandi M (2009) Idiotype vaccines for lymphoma: prof-of-principles and clinical trial failures. Nat Rev Cancer 9:675–681PubMedCrossRefGoogle Scholar
  5. Bendandi M, Marillonnet S, Kandzia R et al (2010) Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin’s lymphoma. Ann Oncol 21(12):2420–2427PubMedCrossRefGoogle Scholar
  6. Bendandi M, Becerra C et al (2011a) Idiotypic vaccination of patients with relapsed follicular lymphoma using a novel vaccine formulation including a tobacco plant-produced tumor specific idiotype. Blood (ASH annual meeting abstracts) 118:1649Google Scholar
  7. Bendandi et al (2011b) Single agent bendamustine is an effective pre-vaccine treatment for patients with relapsed follicular lymphoma undergoing idiotypic vaccination blood (ASH annual meeting abstracts), 118: 2691Google Scholar
  8. CAMI (2011) Multipurpose prevention technologies for reproductive health. Report of a symposium, Washington, DCGoogle Scholar
  9. Capodicasa C, Chiani P, Bromuro C et al (2011) Plant production of anti-glucan antibodies for immunotherapy of fungal infections in humans. Plant Biotech J 9:776–787CrossRefGoogle Scholar
  10. Castilho A, Strasser R, Stadlmann J et al (2010) In planta protein sialylation through overexpression of the respective mammalian pathway. J Biol Chem 285:15923–15930PubMedCrossRefGoogle Scholar
  11. Castilho A, Bohorova N, Grass J, Bohorov O, Zeitlin L, Whaley K, Altmann F, Steinkellner H (2011) Rapid high yield production of different glycoforms of ebola virus monoclonal antibody. PLoS One 6:e26040PubMedCrossRefGoogle Scholar
  12. Chargelegue D, Drake PMW, Obregon P et al (2005) Highly immunogenic and protective recombinant vaccine candidate expressed in transgenic plant. Infect Immun 73:5915–5922PubMedCrossRefGoogle Scholar
  13. Cone RA, Whaley KJ (1994) Monoclonal antibodies for reproductive health: preventing sexual transmission of disease and pregnancy with topically applied antibodies. Am J Reprod Immunol 32:114–131PubMedCrossRefGoogle Scholar
  14. De Muynck B, Navarre C, Boutry M (2010) Production of antibodies in plants: status after twenty years. Plant Biotech J 8:529–563CrossRefGoogle Scholar
  15. Falsey AR, Walsh EE (2000) Respiratory syncytial virus infection in adults. Clin Microbiol Rev 13:371–384PubMedCrossRefGoogle Scholar
  16. FDA (2004) Challenge and opportunity on the critical path to new medical products, food and drug administrationGoogle Scholar
  17. Giritch A, Marillonnet S, Engler C et al (2006) Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. PNAS 103:14701–14706PubMedCrossRefGoogle Scholar
  18. Gomord V, Fitchette AC, Menu Bouaouiche L et al (2010) Plant-specific glycosylation patterns in the context of therapeutic protein production. Plant Biotech J 8:564–587CrossRefGoogle Scholar
  19. Han LL, Alexander JP, Anderson LJ (1999) Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 179:25–30PubMedCrossRefGoogle Scholar
  20. Huang Z, Phoolcharoen W, Lai H et al (2010) High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system. Biotechnol Bioeng 106:9–17PubMedGoogle Scholar
  21. Hudis CA (2007) Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 357:39–51PubMedCrossRefGoogle Scholar
  22. Hudziak RM et al (1989) p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 3:1165–1172Google Scholar
  23. Joffe S, Ray GT, Escobar GJ et al (1999) Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatr 104:419–427CrossRefGoogle Scholar
  24. Kelley B (2007) Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol Prog 23:995–1008PubMedGoogle Scholar
  25. Klimyuk V et al. (2012) Production of recombinant antigens and antibodies in nicotiana benthamiana using magnifection technology: GMP-compliant facilities for Small- and Large-Scale Manufacturing (THIS BOOK)Google Scholar
  26. Komarova TS, Kosorukov SV et al (2011) Plant-made trastuzumab (herceptin) inhibits HER2/Neu+ cell proliferation and retards tumor growth. PLoS One 6:e17541PubMedCrossRefGoogle Scholar
  27. Lai H, Engle M, Fuchs A et al (2010) Monoclonal antibody produced in plants efficiently treats west nile virus infection in mice. PNAS 107:2419–2424PubMedCrossRefGoogle Scholar
  28. Lai H, He J, Engle M et al (2012) Robust production of virus-like particles and monoclonal antibodies with geminiviral replicon vectors in lettuce. Plant Biotech J 10:95–104CrossRefGoogle Scholar
  29. Lopez-Diaz CA, Inoges S (2009) Future of idiotypic vaccination for B-cell lymphoma. Expert Rev Vaccines 8:43–50CrossRefGoogle Scholar
  30. McCormick AA, Reinl SJ et al (2003) Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. J Immunol Methods 278:95–104PubMedCrossRefGoogle Scholar
  31. McCormick AA, Reddy S et al (2008) Plant-produced idiotype vaccines for the treatment of non-Hodgkin’s lymphoma: safety and immunogenicity in a phase I clinical study. PNAS 105:10131–10136PubMedCrossRefGoogle Scholar
  32. Morris G et al (2010) A prospective randomized double blind placebo-controlled phase 1 pharmacokinetic and safety study of a vaginal microbicide gel containing three potent broadly neutralizing monoclonal antibodies (2F5, 2G12, 4E10) (MabGel). Microbicides (Abstract LB1)Google Scholar
  33. Neal LM et al (2010) A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin. Infect Immun 78:552–61Google Scholar
  34. Niwa R et al (2004) Defucosylated chimeric anti-CC chemokine receptor 4 IgGl with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 64:2127–2133PubMedCrossRefGoogle Scholar
  35. O’Hara JM, Whaley KJ, Pauly M (2012) Plant-based expression of a partially humanized neutralizing monoclonal IgG directed against an immunodominant epitope on the ricin toxin A subunit. Vaccine 30:1239–1243PubMedCrossRefGoogle Scholar
  36. O’Hara JM, Neal LM, McCarthy EA et al (2010) Folding domains within the ricin toxin A subunit as targets of protective antibodies. Vaccine 28:7035–7046PubMedCrossRefGoogle Scholar
  37. Olsnes S (2004) The history of ricin, abrin and related toxins. Toxicon 44:361–370PubMedCrossRefGoogle Scholar
  38. Phoolcharoen W, Bhoo SH, Lai H, Ma J, Arntzen CJ, Chen Q, Mason HS (2011a) Expression of an immunogenic ebola immune complex in nicotiana benthamiana. Plant Biotech J 9:807–816CrossRefGoogle Scholar
  39. Phoolcharoen W, Dye JM, Kilbourne J, Piensook K, Pratt WD, Arntzen CJ, Chen Q, Mason HS, Herbst-Kralovetz MM (2011b) A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. PNAS 108:20695–20700PubMedCrossRefGoogle Scholar
  40. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672PubMedCrossRefGoogle Scholar
  41. Pogue GP, Vojdani F, Palmer KE et al (2010) Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotech J 8:638–654CrossRefGoogle Scholar
  42. Roeckl-Wiedmann I, Liese JG, Grill E et al (2003) Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 162:237–244PubMedGoogle Scholar
  43. Sainsbury F, Lomonossoff GP (2008) Extremely high-level and rapid protein production in plants without the use of viral replication. Plant Physiol 148:1212–1218PubMedCrossRefGoogle Scholar
  44. Sainsbury F, Sack M, Stadlmann J et al (2010) Rapid transient production in plants by replicating and non-replicating vectors yields high quality functional anti-HIV antibody. PLoS One 5:1–10CrossRefGoogle Scholar
  45. Schahs M, Strasser R, Stadlmann J et al (2007) Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. Plant Biotech J 5:657–663CrossRefGoogle Scholar
  46. Shields RL et al (2002) Lack of fucose on human IgGl N-linked oligosaccharide improves binding to human FcyRIII and antibody-dependent cellular toxicity. J Biol Chem 277:26733–26740PubMedCrossRefGoogle Scholar
  47. Shinkawa T et al (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgGl complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278:3466–3473PubMedCrossRefGoogle Scholar
  48. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRefGoogle Scholar
  49. Smith I, Procter M, Gelber RD et al (2007) Two year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 369:29–36PubMedCrossRefGoogle Scholar
  50. Stirpe F (2004) Ribosome-inactivating proteins. Toxicon 15:371–383CrossRefGoogle Scholar
  51. Strasser R, Stadlmann J, Schahs M et al (2008) Generation of glyco-engineered nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotech J 6:392–402CrossRefGoogle Scholar
  52. Strasser R, Castilho A, Stadlmann J et al (2009) Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous beta1,4-galactosylated N-glycan profile. J Biol Chem 284:20479–20485PubMedCrossRefGoogle Scholar
  53. Vezina L-P, Faye L, Lerouge P et al (2009) Transient co-expression for fast and high-yield production of antibodies with human-like N-glycans in plants. Plant Biotech J 7:442–455CrossRefGoogle Scholar
  54. Vogel AM, McKinlay MJ, Ashton T et al (2002) Cost-effectiveness of palivizumab in New Zealand. J Paediatr Child Health 38:352–357PubMedCrossRefGoogle Scholar
  55. Werner S, Marillonnet S, Hause G et al (2006) Immunoabsorbent nanoparticles based on a tobamorvirus displaying protein A. PNAS 103:17678–17717PubMedCrossRefGoogle Scholar
  56. Whaley KJ, Hiatt A, Zeitlin A (2011) Emerging antibody products and nicotiana manufacturing. Hum Vaccines 7:349–356CrossRefGoogle Scholar
  57. Wilson JA, Hevey M, Bakken R et al (2000) Epitopes involved in antibody-mediated protection from ebola virus. Science 287:1664–1666PubMedCrossRefGoogle Scholar
  58. Yermakova A, Mantis NJ (2011) Protective immunity to ricin toxin conferred by antibodies against the toxin’s binding subunit (RTB). Vaccine 29:7925–7935PubMedCrossRefGoogle Scholar
  59. Zeitlin L, Pettitt J, Scully C et al (2011) Enhanced potency of a fucose-free monoclonal antibody being developed as an ebola virus immunoprotectant. PNAS 108:20690–20694PubMedCrossRefGoogle Scholar
  60. Zeitlin L et al (2012) Prophylactic and therapeutic testing of nicotiana-derived anti-RSV human monoclonal antibodies in the cotton rat model. (Submitted)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Kevin J. Whaley
    • 1
    Email author
  • Josh Morton
    • 2
  • Steve Hume
    • 2
  • Ernie Hiatt
    • 2
  • Barry Bratcher
    • 2
  • Victor Klimyuk
    • 3
  • Andrew Hiatt
    • 1
  • Michael Pauly
    • 1
  • Larry Zeitlin
    • 1
  1. 1.Mapp Biopharmaceutical IncSan DiegoUSA
  2. 2.Kentucky BioProcessingOwensboroUSA
  3. 3.Icon Genetics GmBHHalle (Saale)Germany

Personalised recommendations